IN8bio

IN8bio is a leader in the clinical development of gamma-delta T cell therapies, a promising but challenging class of cellular immunotherapy. The company's core innovation is its DeltEx™ platform, which enables the genetic engineering and scalable manufacturing of γδ T cells, including its proprietary Drug Resistant Immunotherapy (DRI) approach designed to work in tandem with chemotherapy. With multiple clinical-stage assets, most notably INB-400 in a Phase 2 trial for glioblastoma, IN8bio is strategically positioned to address significant unmet needs in oncology, though its success hinges on clinical validation and navigating a complex competitive and financial landscape.

The DeltEx™ platform is an integrated suite for developing gamma-delta T cell therapies, featuring proprietary genetic engineering (including Drug Resistant Immunotherapy and non-signaling CARs) and scalable manufacturing processes for autologous, allogeneic, and iPSC-derived cell products.